Comparative Pharmacology
Head-to-head clinical analysis: DIVIGEL versus STILBESTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIVIGEL versus STILBESTROL.
DIVIGEL vs STILBESTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estradiol replacement therapy; binds to estrogen receptors, activating transcription of estrogen-responsive genes, leading to proliferation of endometrial and breast epithelium, and modulation of gonadotropin secretion.
Synthetic nonsteroidal estrogen that acts by binding to estrogen receptors (ERα and ERβ), leading to translocation to the nucleus, modulation of gene transcription, and promotion of estrogenic effects in target tissues.
Transdermal gel: 0.25-1.0 g applied once daily to upper thigh, abdomen, or upper arm. Each gram contains 1 mg estradiol.
0.5 to 2 mg orally once daily; or 25 mg intramuscularly once daily for 5 days; for prostate cancer: 1 to 3 mg orally once daily.
None Documented
None Documented
Clinical Note
moderateDiethylstilbestrol + Digoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDiethylstilbestrol + Digitoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDiethylstilbestrol + Deslanoside
"Diethylstilbestrol may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDiethylstilbestrol + Acetyldigitoxin
Terminal elimination half-life of estradiol is 13-15 hours; clinical context: due to enterohepatic recirculation, serum levels may fluctuate; transdermal delivery avoids first-pass hepatic metabolism, resulting in more stable levels
Terminal elimination half-life is approximately 24-48 hours, with a prolonged phase due to enterohepatic recirculation; requires dosing adjustment in hepatic impairment.
Urine (approximately 90-95% as glucuronide and sulfate conjugates, with less than 5% as unchanged drug); feces (approximately 5-10% via biliary excretion)
Renal excretion of glucuronide and sulfate conjugates accounts for approximately 60-80% of an administered dose; biliary/fecal excretion accounts for 15-30%; less than 5% is excreted unchanged in urine.
Category C
Category C
Estrogen
Estrogen
"Diethylstilbestrol may decrease the cardiotoxic activities of Acetyldigitoxin."